evels of Adropin and Irisin in periodontal disease and Diabetes
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2024/07/069992
- Lead Sponsor
- Dr Swathi S Kumar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients who have not received any periodontal treatment in
previous six months.
2. Patients diagnosed with T2DM as per
American Diabetes Association criteria (2019).
3. Patients with a diagnosis of Generalized Periodontitis as per World Workshop Classification criteria (2017).
1. Smokers and alcoholics.
2. Patients with systemic diseases like hypertension, cardiovascular
diseases, rheumatoid arthritis, tumours, autoimmune diseases and
renal diseases.
3. Pregnant, lactating females and post menopausal women.
4. Any other systemic disease which can alter the course of
periodontal disease.
5. Patients on any medication like anti-inflammatory drugs,
antibiotics and anti-epileptic drugs in the past 6 months.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparatively evaluate salivary and serum levels of Adropin and Irisin in periodontitis and T2DM patients. <br/ ><br>Explore any correlation of Adropin and Irisin and clinical parameters.Timepoint: Baseline
- Secondary Outcome Measures
Name Time Method Explore any correlation of Adropin with irisin and clinical, biochemical & demographic parameters.Timepoint: Baseline